McNeil presses FDA on analgesic/sleep-aid combo
This article was originally published in The Tan Sheet
Executive Summary
The Johnson & Johnson subsidiary asks FDA to consider data supporting a Nighttime Sleep-Aid OTC monograph indication for "relief of occasional sleeplessness when associated with minor aches and pains" in a drug product containing diphenhydramine and acetaminophen - such as McNeil's Tylenol PM. The firm's March 31 1letter notes it generated data on the drug combination's effects using the same model Wyeth used to generate data in support of the new drug application for Advil PM (ibuprofen/diphenhydramine), which launched in 2006 to challenge Tylenol PM (2"The Tan Sheet" Jan. 9, 2006). McNeil's letter follows FDA's recent 3determination that data on diphenhydramine and acetaminophen the Consumer Healthcare Products Association submitted were insufficient to demonstrate "'each active ingredient makes a contribution to the claimed effect(s)' as required by the OTC combination policy.
You may also be interested in...
Wyeth’s Advil PM Approved By FDA; Sleep Aid To Challenge Tylenol PM?
Wyeth is entering the combination sleep aid/pain reliever category with its new Advil PM, recently approved by FDA for over-the-counter sale
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.